Cross-protection of a porcine circovirus types 2a/b (PCV-2a/b) and Mycoplasma hyopneumoniae trivalent vaccine against a dual PCV-2e and Mycoplasma hyopneumoniae challenge.

The purpose of this experimental study was to determine the cross-protection of a new trivalent vaccine containing porcine circovirus types 2a/b (PCV-2a/b) and Mycoplasma hyopneumoniae. Pigs were vaccinated intramuscularly at 21 days of age, then challenged at 42 days of age with a dual PCV-2e and M. hyopneumoniae challenge. Growth performance was significantly improved during the experimental period (21 to 63 days of age) in vaccinated-challenged pigs compared to unvaccinated-challenged pigs. Pigs that were vaccinated and challenged elicited a significant amount of PCV-2e- and M. hyopneumoniae-specific interferon-γ secreting cells (IFN-γ-SC) and reduced the levels of PCV-2e viremia and laryngeal shedding. The results of the present study demonstrated that a trivalent vaccine provided cross-protection against a dual PCV-2e and M. hyopneumoniae challenge.